Strides Pharma Science Ltd.
| BSE: 532531 | Sector: Health care |
| NSE: STAR | ISIN Code: INE939A01011 |
| BSE 00:00 | 25 Sep | 660.20 |
18.95 (2.96%) |
OPEN
646.05 |
HIGH
666.85 |
LOW
646.05 |
| NSE 00:00 | 25 Sep | 661.45 |
20.10 (3.13%) |
OPEN
650.00 |
HIGH
666.90 |
LOW
647.00 |
| OPEN | 646.05 |
| PREVIOUS CLOSE | 641.25 |
| VOLUME | 132654 |
| 52-Week high | 745.15 |
| 52-Week low | 271.00 |
| P/E | 64.92 |
| Mkt Cap.(Rs cr) | 5,917 |
| Buy Price | 660.20 |
| Buy Qty | 67.00 |
| Sell Price | 660.45 |
| Sell Qty | 243.00 |
Strides Pharma Science Ltd. (STAR) - News Sector
-
Dr Reddy's enters Rs 28,000 cr market with multiple sclerosis drug in US
6.22 pm | 26 Sep 2020 | Press Trust of India
The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said i...
-
Cipla surges 5% on USFDA approval for dimethyl fumarate DR capsules
1.15 pm | 25 Sep 2020 | Business Standard
The drug, indicated for treatment of relapsing forms of multiple sclerosis, had annual US sales of US$3.8 billion as per IQVIA MAT July 2020.
-
Granules India up 5% on USFDA approval for generic Aleve PM tablets
12.40 pm | 25 Sep 2020 | Business Standard
According to media reports, global private equity firms have expressed interest in acquiring a controlling stake in the company
-
Stocks to watch: IT stks, Cipla, RIL, TCS, Tata Coffee, Mahindra & Mahindra
8.52 am | 25 Sep 2020 | Business Standard
Here's a list of stocks that may trade actively in today's session
-
Stock recommendations by Anand Rathi: Sell Piramal Enterprises, L&T Finance
8.08 am | 25 Sep 2020 | Business Standard
The momentum oscillator MACD has provided fresh sell crossover on the weekly scale for Piramal's stock
-
Syngene: Investors with long term view should look at the stock on dips
1.17 am | 25 Sep 2020 | Business Standard
While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger
-
Nearly half of BSE 500 stocks underperform market since March low
1.05 am | 25 Sep 2020 | Business Standard
The S&P BSE 500 index, which accounts for 94 per cent market capitalisation of BSE listed companies, has gained 45 per cent from its March 24 low.
-
Emami, IPCA Labs: 5 defensive stocks you can buy in the current market
12.08 pm | 24 Sep 2020 | Business Standard
Despite the market correction, there are some stocks from the FMCG and pharma sectors - considered classic defensive plays - that can be bought from a...
-
Emami, IPCA Labs: 5 defensive stocks you can buy in the current market
12.08 pm | 24 Sep 2020 | Business Standard
Despite the market correction, there are some stocks from the FMCG and pharma sectors - considered classic defensive plays - that can be bought from a...
-
Emami, IPCA Labs: 5 defensive stocks you can buy in the current market
12.08 pm | 24 Sep 2020 | Business Standard
Despite the market correction, there are some stocks from the FMCG and pharma sectors - considered classic defensive plays - that can be bought from a...
-
Apollo Hospitals surges 21% in 2 weeks post Q1 results; stock hits new high
12.05 pm | 24 Sep 2020 | Business Standard
Analysts see Apollo going back to its hospital margin expansion trajectory in FY22 to help drive cash generation and debt reduction
-
Syngene Int'l hits record high in a weak market, rallies 26% in two weeks
10.46 am | 24 Sep 2020 | Business Standard
The stock rallied 6.5 per cent to Rs 596.85, surpassing its previous high Rs 594.75, touched on September 15, 2020, on the BSE.
-
India's Covid diplomacy: US to Russia, Delhi part of every vaccine alliance
1.47 am | 24 Sep 2020 | Business Standard
India is party to Sputnik-V, the vaccine under development jointly by Russia's Gamaleya National Research Institute of Epidemiology and Microbiology a...
-
Double-digit sales dip in anti-infective segment to weigh on Alkem Labs
12.56 am | 23 Sep 2020 | Business Standard
Higher chronic sales, US market could offset some of the weakness in sales growth
-
Higher sales in domestic market, lower costs bode well for Glenmark
12.17 am | 22 Sep 2020 | Business Standard
The other trigger for the stock is the cost savings from lower investments in R&D and fund raising for innovation research
-
New Covid-19 drugs provide additional fuel as Cipla fires on all cylinders
2.23 am | 19 Sep 2020 | Business Standard
Firm domestic sales and positive outlook in the US point to robust earnings
-
Sensex ends 134 pts lower, Nifty settles at 11,505; Nifty Pharma jumps 5%
4.23 pm | 18 Sep 2020 | Business Standard
All that happened in the markets today
-
Dr Reddy's reclaims spot as India's 2nd most valuable pharma company
2.47 pm | 18 Sep 2020 | Business Standard
At 02:17 pm, Dr Reddy's Labs market cap stood at Rs 90,348 crore while that of Divi's Laboratories stood at Rs 89,119 crore, BSE data show
-
Dr Reddy's reclaims spot as India's 2nd most valuable pharma company
2.47 pm | 18 Sep 2020 | Business Standard
At 02:17 pm, Dr Reddy's Labs market cap stood at Rs 90,348 crore while that of Divi's Laboratories stood at Rs 89,119 crore, BSE data show
-
Dr Reddy's reclaims spot as India's 2nd most valuable pharma company
2.47 pm | 18 Sep 2020 | Business Standard
At 02:17 pm, Dr Reddy's Labs market cap stood at Rs 90,348 crore while that of Divi's Laboratories stood at Rs 89,119 crore, BSE data show
Quick Links for Strides Pharma Science:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
